Drug intelligence / Profile preview

magaldrate

Development stage
Phase 4
Lead developer
Altana
Modality
Small Molecules
Administration
Oral
01

Overview

Magaldrate is an antacid composed of magnesium and aluminum hydroxides. It is used to relieve symptoms associated with excess stomach acid such as heartburn (acid reflux), indigestion (dyspepsia), sour stomach and upset stomach. It is also indicated for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers (gastric and duodenal ulcers), esophagitis and hyperphosphatemia. The drug works by neutralizing gastric acid in the stomach; it reacts rapidly with hydrochloric acid to form water and other neutral compounds. The combination of rapid-acting magnesium hydroxide and slow-acting aluminum hydroxide provides both immediate relief and sustained action against acidity. Aluminum’s constipating effect is balanced by the laxative effect of magnesium[1][2][3][4][5][7]. Magaldrate has been discontinued in some markets including the United States but remains available internationally under various brand names[4][6].

Brand names
Ron AcidRiopanLowsiumMaosonRi-MagLosospanMagalatMagal-DMagaldrat-ratiopharmMagaldraxMagaltopMaganMagionMagnadroxMagralibiMagsilonMalsimMaraxMarloxMasediMegacaineMegcidMetadrateMiopan
Other names
aluminum hydroxide/magnesium hydroxide

Beyond the preview

Go deeper on magaldrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on magaldrate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call